Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
No open-market purchases versus $1.4M in reported salesOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Stewart Richard Alistair | Director | Aug 19 '26 | Sale | $8.49 | 20,626 | $175,177 | 208,249 | Aug 21 04:30 PM |
| Stewart Richard Alistair | Director | Aug 19 '26 | Proposed Sale | $7.52 | 20,626 | $155,108 | — | Aug 19 09:16 AM |
| Oki Mark K | Chief Financial Officer | Sep 18 '25 | Option Exercise | $0.00 | 168,000 | $0 | 178,000 | Sep 22 04:31 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.